Treatment is still under review by the European Medicines Agency (EMA)
Merck
Merck's Vice President said it might create problems for some patients taking drugs for other medical conditions
If cleared by regulators, it would likely be a game-changer in the ongoing global pandemic fight
She said the monoclonal therapy would be available by the end of 2021
The easy-to-administer treatment has halved the risk of hospitalization or death from Covid-19 for people with mild to moderate symptoms
Merck said it is asking for authorisation for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalisation